GleamWall
中文EN

SILO Silo Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1514183 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.0%
TTM net income YoY26.7%
TTM EPS YoY159.8%
Revenue 3-yr CAGR-20.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12,534.1%
Net margin-10,319.0%
FCF margin—
EBITDA margin—

Returns

ROE-55.3%
ROA-49.0%
ROIC (approx.)-207.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets4.0%
Debt / equity0.00x
Current ratio24.43x
Interest coverage-112.82x

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-09-302026Q2*2026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$18,026$18,026$18,025$18,025$18,026$18,026
Cost of revenue—$0$20,688$20,689$20,687$1,459$1,460$1,460
Gross profit—$0-$2,662-$2,663-$2,662$16,566$16,566$16,566
R&D expense$559,091$298,418$1.01M$306,005$543,615$717,247$593,962$1.08M
Operating income-$1.21M-$928,949-$1.59M-$786,524-$1.15M-$1.25M-$1.09M-$1.81M
Interest expense$1,114$2,865$3,373$32,702$886$1,648$2,066$274
Pretax income-$358,743-$832,829-$1.65M-$881,530-$1.11M-$1.20M-$1.03M-$1.73M
Net income-$358,743-$832,829-$1.65M-$881,530-$1.11M-$1.20M-$1.03M-$1.73M
EPS (basic)-0.21-0.76-0.12—-1.79-2.88-0.23—
EPS (diluted)-0.21-0.76-0.12—-1.79-2.88-0.23—
Weighted avg. shares (diluted)1.75M1.10M13.71M—622,090418,6494.48M—
Balance sheet
Cash & equivalents$6.09M$3.28M$3.90M$4.75M$3.92M$4.33M$3.14M$3.91M
Short-term investments$1.96M$1.95M$2.13M$2.11M$1.95M$1.93M$2.31M$3.17M
Current assets$8.59M$5.71M$6.80M$7.39M$6.16M$6.37M$5.60M$7.11M
Intangibles$208,562$211,500$214,438$217,375$220,312$223,250$238,123$241,215
Total assets$8.80M$5.95M$7.02M$7.61M$6.38M$6.65M$5.90M$7.41M
Current liabilities$351,453$1.07M$704,845$650,183$708,339$1.05M$1.19M$1.66M
Total liabilities$351,453$1.07M$1.34M$1.30M$1.38M$1.74M$1.89M$2.38M
Shareholders' equity$8.44M$4.89M$5.68M$6.31M$5.01M$4.92M$4.01M$5.03M
Shares outstanding1.89M1.13M16.27M887,88610.46M8.65M4.48M4.48M
Cash flow statement
Operating cash flow-$603,534-$781,861-$822,623-$780,278-$955,493-$1.29M-$1.64M-$917,432
Investing cash flow-$17,337$183,439-$23,563-$519,988-$95,474$388,102$871,381-$37,659
Financing cash flow$3.43M——$2.13M$634,922——$0
Stock-based compensation$9,352$39,174$56,619$52,309$47,267-$161,024$178,469$395,310

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.